Dose-Escalation Study of Amygdalar Transcranial Focused Ultrasound in Healthy Volunteers
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Transcranial focused ultrasound (tFUS) is a promising noninvasive technique for modulating deep brain structures, but the optimal and safe intensity range for neuromodulation remains unclear. Current FDA intensity limits, designed for diagnostic use rather than therapy, may limit the potential effectiveness of tFUS.
Objective
This study aimed to evaluate the safety and preliminary efficacy of escalating tFUS intensities targeting the right amygdala in healthy volunteers, including intensity levels exceeding current FDA diagnostic ultrasound limits.
Methods
Ten healthy adults (mean age = 19.5 ± 1.4 years; 70% female) participated in a within-subject, repeated-measures design. Each received four randomized tFUS stimulation conditions (ISPTA.3 = 0.72–10.08 W/cm²) using the BX Pulsar 1002 system. Structural MRI was performed before each stimulation to monitor safety. Affective modulation was assessed pre- and post-stimulation via the International Affective Picture Set (IAPS) task, measuring changes in valence and arousal ratings. Acoustic modeling was conducted using BabelBrain to estimate intracranial energy deposition.
Results
No adverse events or MRI-detectable structural changes (e.g., edema, hemorrhage, or microstructural abnormalities) occurred under any stimulation condition. Behavioral analyses revealed no significant overall effects of intensity on affective measures. Comparisons between excitatory and inhibitory paradigms showed no significant differences.
Conclusions
tFUS of the right amygdala at intensities up to 10.08 W/cm² ISPTA.3—over 14 times the FDA diagnostic limit—was well tolerated and produced no structural or subjective adverse effects. These findings support the safety of higher-intensity tFUS and justify further investigation in larger and clinical populations to explore potential dose–response effects on emotion regulation.
